---
title: "Alibaba Health Information Technology Limited (00241.HK)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/00241.HK.md"
symbol: "00241.HK"
name: "Alibaba Health Information Technology Limited"
industry: "Drug Retail"
---

# Alibaba Health Information Technology Limited (00241.HK)

| Item | Detail |
|------|--------|
| Industry | Drug Retail |
| Location | HK Market |
| Website | [www.alihealth.cn](https://www.alihealth.cn) |

## Company Profile

Alibaba Health Information Technology Limited, an investment holding company, engages in the pharmaceutical direct sales, pharmaceutical e-commerce platform, and healthcare and digital services businesses in Mainland China and Hong Kong. The company offers a range of prescription and over-the-counte...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-21T04:30:11.000Z

**Overall: B (0.22)**

**Industry**: Drug Retail

| Metric | Value |
|--------|-------|
| Industry Ranking | 3 / 7 |
| Industry Median | B |
| Industry Average | B |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Large - The company has stable operations, allowing for dependable long-term returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 15.31% |  |
| Net Profit YoY | 58.33% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 5.09 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 97.86B |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 35.68B |  |


**Multi Score**: B

#### Profit Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 11.75% | B |
| Profit Margin | 5.84% | B |
| Gross Margin | 25.06% | C |

#### Growth Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 15.31% | B |
| Net Profit YoY | 58.33% | B |
| Total Assets YoY | 13.20% | B |
| Net Assets YoY | 13.61% | B |

#### Cash Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | 1710.88% | B |
| OCF YoY | 15.31% | B |

#### Operating Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 1.52 | A |

#### Debt Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 24.49% | B |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Alibaba Health Information Technology Limited",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "11.75%",
          "rating": "B"
        },
        {
          "name": "Profit Margin",
          "value": "5.84%",
          "rating": "B"
        },
        {
          "name": "Gross Margin",
          "value": "25.06%",
          "rating": "C"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "B",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "15.31%",
          "rating": "B"
        },
        {
          "name": "Net Profit YoY",
          "value": "58.33%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "13.20%",
          "rating": "B"
        },
        {
          "name": "Net Assets YoY",
          "value": "13.61%",
          "rating": "B"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "B",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "1710.88%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "15.31%",
          "rating": "B"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "A",
      "indicators": [
        {
          "name": "Turnover",
          "value": "1.52",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "B",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "24.49%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | JD HEALTH (HK.6618) | B | B | B | B | B | B |
| 02 | JD HEALTH-R (HK.86618) | B | B | B | B | B | B |
| 03 | ALI HEALTH (HK.241) | B | B | A | B | B | B |
| 04 | PA GOODDOCTOR (HK.1833) | C | B | C | B | A | B |
| 05 | FANGZHOU JIANKE (HK.6086) | D | A | A | E | D | C |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 46.29 | 3/7 | 63.03 | 54.86 | 46.86 |
| PB | 5.09 | 6/7 | 5.44 | 4.86 | 4.32 |
| PS (TTM) | 2.71 | 6/7 | 2.92 | 2.61 | 2.30 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-17T16:00:00.000Z

Total Analysts: **18**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 10 | 56% |
| Overweight | 1 | 6% |
| Hold | 5 | 28% |
| Underweight | 0 | 0% |
| Sell | 2 | 11% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 6.05 |
| Highest Target | 12.10 |
| Lowest Target | 4.67 |

## References

- [Company Overview](https://longbridge.com/en/quote/00241.HK/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/00241.HK/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/00241.HK/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.